Senegal

The primary regulatory authority for health products in Senegal is the Direction de la Pharmacie et du Médicament (DPM), operating under the Ministère de la Santé et de l'Action Sociale. The principal legislative framework is governed by the Code de la Santé Publique and supplementary ministerial decrees that regulate the importation, registration, distribution, and post-market surveillance of pharmaceuticals, medical devices, diagnostics, and increasingly digital health solutions. All health products intended for the Senegalese market must obtain a Marketing Authorization (Autorisation de Mise sur le Marché, AMM) prior to commercialization, and the DPM coordinates technical evaluation in collaboration with the Laboratoire National de Contrôle des Médicaments (LNCM) for quality testing. Senegal is also an active member of the West African Health Organisation (WAHO) and participates in the ECOWAS regional harmonization framework, which seeks to align registration procedures across member states.

Applicants for product registration are required to appoint a local representative or licensed pharmaceutical importer domiciled in Senegal, who assumes legal and regulatory responsibility for the product on the market. Dossier submissions are generally expected to follow the Common Technical Document (CTD) format, and the DPM increasingly accepts dossiers reviewed or approved by recognized reference authorities such as the European Medicines Agency (EMA), the US Food and Drug Administration (FDA), or those carrying WHO Prequalification status, which can facilitate an expedited review pathway. Medical devices and in-vitro diagnostics face a less formalized but evolving registration pathway, with classification and conformity documentation such as CE marking or equivalent accepted as supporting evidence. Recent reforms have focused on strengthening pharmacovigilance infrastructure, digitizing submission workflows, and aligning national standards more closely with the African Medicines Regulatory Harmonisation (AMRH) initiative under the African Union Development Agency (AUDA-NEPAD), reflecting Senegal's broader commitment to improved regulatory capacity.

Public procurement of health products in Senegal is centrally coordinated through the Centrale d'Achat des Médicaments Essentiels, Vaccins et Consommables Médicaux (CAMEC), which serves as the national central medical store and primary procurement entity for essential medicines, vaccines, diagnostics, and medical consumables destined for the public health system. CAMEC operates under the oversight of the Ministère de la Santé et de l'Action Sociale and manages tendering processes in accordance with the national public procurement code administered by the Direction Centrale des Marchés Publics (DCMP) and overseen by the Autorité de Régulation des Marchés Publics (ARMP). Public health facilities, regional health districts, and national hospitals procure primarily through CAMEC-negotiated frameworks or direct government tenders, with product registration and local regulatory compliance being mandatory prerequisites for participation in any public tender.

The private sector channel in Senegal operates through licensed pharmaceutical wholesalers and distributors who supply private clinics, pharmacies, and mission-sector facilities, representing a significant and growing share of overall health product consumption. Donor-funded procurement plays a substantial role in the Senegalese health market, with organizations such as UNICEF Supply Division, the Global Fund to Fight AIDS, Tuberculosis and Malaria, USAID through its implementing partners, Gavi the Vaccine Alliance, and UNFPA financing and procuring considerable volumes of medicines, vaccines, diagnostics, reproductive health commodities, and medical devices, often bypassing standard national tender processes through direct international procurement mechanisms. These donor channels frequently require WHO Prequalification or equivalent regulatory approval as a condition of supply eligibility. While Senegal does not yet have a robust local pharmaceutical manufacturing base, the government has expressed policy intentions to support regional and local production capacity as part of the broader African Union Pharmaceutical Manufacturing Plan for Africa, and preferential consideration for locally or regionally manufactured products may increasingly feature in future procurement policy frameworks.